<DOC>
	<DOCNO>NCT00834210</DOCNO>
	<brief_summary>A 12-week evaluation safety efficacy dapsone gel 5 % use tazarotene cream 0.1 % compare tazarotene cream 0.1 % monotherapy treat moderate severe facial acne vulgaris</brief_summary>
	<brief_title>Dapsone Gel 5 % Tazarotene Cream 0.1 % Versus Tazarotene Cream 0.1 % Monotherapy Facial Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Facial acne vulgaris characterize follow : 30100 facial inflammatory lesion ; 25100 facial noninflammatory lesion ; stable disease , nonrapidly regress facial acne vulgaris ; , 3 nodule and/or cyst ( diameter 1cm great ) . Female subject childbearing potential must negative pregnancy test baseline practice reliable method contraception throughout study Noncompliance washout period ; history clinically significant anemia hemolysis ; skin disease/disorder might interfere diagnosis evaluation acne vulgaris ; allergy sensitivity component test medication</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>